SEARCH:   Advanced

Blood, 15 September 2006, Vol. 108, No. 6, pp. 1809-1820. Prepublished online as a Blood First Edition Paper on May 18, 2006; DOI 10.1182/blood-2006-02-005686. This Article Full Text (PDF) All Versions of this Article: blood-2006-02-005686v1 108/6/1809    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Baccarani, M. Articles by Hehlmann, R. Search for Related Content PubMed PubMed Citation Articles by Baccarani, M. Articles by Hehlmann, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 24, 2006 Accepted May 2, 2006 Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet Michele Baccarani*, Giuseppe Saglio, John Goldman, Andreas Hochhaus, Bengt Simonsson, Frederick Appelbaum, Jane Apperley, Francisco Cervantes, Jorge Cortes, Michael Deininger, Alois Gratwohl, Francois Guilhot, Mary Horowitz, Timothy Hughes, Hagop Kantarjian, Richard Larson, Dietger Niederwieser, Richard Silver, and Rudiger Hehlmann Department of Hematology/Oncology "L. and A. Seragnoli", University of Bologna, Italy University of Turin at Orbassano, Turin, Italy Hematology Branch, National Heart, Lung & Blood Institute, NIH, Bethesda, MD, USA Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany Department of Hematology, University Hospital, Uppsala, Sweden Fred Hutchinson Cancer Research Center, Seattle, WA, USA Department of Hematology, Hammersmith Hospital, London, UK Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain MD Anderson Cancer Center, Houston, TX, USA Oregon Health & Science University Cancer Institute, Portland, OR, USA Hematology, University Hospital, Basel, Switzerland Oncology, Hematology and Cell Therapy, Medical Oncology, EA 3805 and Clinical Research Centre,France Centre for International Blood & Marrow Transplant, Medical College of Wisconsin, Milwaukee, USA Institute of Medical and Veterinary Science, Adelaide, Australia University of Chicago, Chicago, IL, USA Department of Hematology and Oncology, University of Leipzig, Germany New York Presbyterian-Weill Cornell Medical Center, New York, NY, USA * Corresponding author; email: baccarani{at}med.unibo.it. The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the available data fully justify critical reassessment of CML management. The panel therefore reviewed treatment of CML since 1998. It confirmed the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT). It recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be IM 400 mg daily. A dose increase of IM, or alloHSCT, or investigational treatments were recommended in case of failure and could be considered in case of suboptimal response. Failure was defined at 3 months (no hematologic response (HR)), 6 months (incomplete HR or no cytogenetic response (CgR)), 12 months (less than partial CgR (Ph+ >35%)), 18 months (less than complete CgR), and in case of HR or CgR loss, or appearance of IM-highly-resistant BCR/ABL mutations. Suboptimal response was defined at 3 months (incomplete HR), 6 months (less than partial CgR), 12 months (less than complete CgR), 18 months (less than major molecular response (MMolR)), and in case of MMolR loss, other mutations or other chromosome abnormalities. The importance of regular monitoring at experienced centers was highlighted. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne, J. Reiffers, M. Molimard, M. Krajinovic, and F.-X. Mahon Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood, September 1, 2008; 112(5): 2024 - 2027. [Abstract] [Full Text] [PDF] H. de Lavallade, J. F. Apperley, J. S. Khorashad, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al. Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis J. Clin. Oncol., July 10, 2008; 26(20): 3358 - 3363. [Abstract] [Full Text] [PDF] E. Jabbour, H. Kantarjian, D. Jones, M. Breeden, G. Garcia-Manero, S. O'Brien, F. Ravandi, G. Borthakur, and J. Cortes Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Blood, July 1, 2008; 112(1): 53 - 55. [Abstract] [Full Text] [PDF] D. K. Hiwase, V. Saunders, D. Hewett, A. Frede, S. Zrim, P. Dang, L. Eadie, L. B. To, J. Melo, S. Kumar, et al. Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications Clin. Cancer Res., June 15, 2008; 14(12): 3881 - 3888. [Abstract] [Full Text] [PDF] N. B. Heaney, M. Copland, K. Stewart, J. Godden, A. N. Parker, I. G. McQuaker, G. M. Smith, C. Crawley, P. Shepherd, and T. L. Holyoake Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia Blood, May 15, 2008; 111(10): 5252 - 5255. [Abstract] [Full Text] [PDF] C. Bressollette-Bodin, A. Claver, D. Boutolleau, P. Chevallier, T. Guillaume, T. Gastinne, P. Moreau, J-L. Harousseau, B.M. Imbert-Marcille, and S. Le Gouill Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient Haematologica, May 1, 2008; 93(5): e39 - e41. [Full Text] [PDF] P. La Rosee, S. Holm-Eriksen, H. Konig, N. Hartel, T. Ernst, J. Debatin, M. C. Mueller, P. Erben, A. Binckebanck, L. Wunderle, et al. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib Haematologica, May 1, 2008; 93(5): 765 - 769. [Abstract] [Full Text] [PDF] F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome Haematologica, May 1, 2008; 93(5): 770 - 774. [Abstract] [Full Text] [PDF] P. Ramirez and J. F. DiPersio Therapy Options in Imatinib Failures Oncologist, April 1, 2008; 13(4): 424 - 434. [Abstract] [Full Text] [PDF] C. Roche-Lestienne, L. Deluche, S. Corm, I. Tigaud, S. Joha, N. Philippe, S. Geffroy, J.-L. Lai, F.-E. Nicolini, C. Preudhomme, et al. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance Blood, April 1, 2008; 111(7): 3735 - 3741. [Abstract] [Full Text] [PDF] S. Fitter, A. L. Dewar, P. Kostakis, L. B. To, T. P. Hughes, M. M. Roberts, K. Lynch, B. Vernon-Roberts, and A. C. W. Zannettino Long-term imatinib therapy promotes bone formation in CML patients Blood, March 1, 2008; 111(5): 2538 - 2547. [Abstract] [Full Text] [PDF] W. Deenik, B. van der Holt, G. E. G. Verhoef, W. M. Smit, M. J. Kersten, H. C. Kluin-Nelemans, L. F. Verdonck, A. Ferrant, A. V. M. B. Schattenberg, J. J. W. M. Janssen, et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia Blood, March 1, 2008; 111(5): 2581 - 2588. [Abstract] [Full Text] [PDF] H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods Blood, February 15, 2008; 111(4): 1774 - 1780. [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] T. Lundan, V. Juvonen, M. C. Mueller, S. Mustjoki, T. Lakkala, V. Kairisto, A. Hochhaus, S. Knuutila, and K. Porkka Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 178 - 185. [Abstract] [Full Text] [PDF] T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica, February 1, 2008; 93(2): 186 - 192. [Abstract] [Full Text] [PDF] H. M Marshall and J. M Hammond Treatment Options in Imatinib-Resistant Chronic Myelogenous Leukemia Ann. Pharmacother., February 1, 2008; 42(2): 259 - 264. [Abstract] [Full Text] [PDF] F. Palandri, I. Iacobucci, G. Martinelli, M. Amabile, A. Poerio, N. Testoni, S. Soverini, F. Castagnetti, A. De Vivo, M. Breccia, et al. Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML J. Clin. Oncol., January 1, 2008; 26(1): 106 - 111. [Abstract] [Full Text] [PDF] J. E. Cortes Imatinib and Beyond--Therapy of CML in 2008 ASCO Educational Book, January 1, 2008; 2008(1): 307 - 312. [Abstract] [Full Text] [PDF] G. Saglio, F. Pane, and G. Martinelli State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317. [Abstract] [Full Text] [PDF] M. W.N. Deininger Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells ASCO Educational Book, January 1, 2008; 2008(1): 318 - 323. [Abstract] [Full Text] [PDF] T. Littlewood, R. Malladi, and A. Peniket No more transplantation in CML? Blood, December 15, 2007; 110(13): 4618 - 4618. [Full Text] [PDF] A. Gratwohl, H. Baldomero, A. Schwendener, M. Gratwohl, J. Apperley, D. Niederwieser, K. Frauendorfer, and for the Joint Accreditation Committee of the Inter Predictability of hematopoietic stem cell transplantation rates Haematologica, December 1, 2007; 92(12): 1679 - 1686. [Abstract] [Full Text] [PDF] S. Branford, J. F. Seymour, A. Grigg, C. Arthur, Z. Rudzki, K. Lynch, and T. Hughes BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria Clin. Cancer Res., December 1, 2007; 13(23): 7080 - 7085. [Abstract] [Full Text] [PDF] D. L. White, V. A. Saunders, P. Dang, J. Engler, A. Venables, S. Zrim, A. Zannettino, K. Lynch, P. W. Manley, and T. Hughes Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood, December 1, 2007; 110(12): 4064 - 4072. [Abstract] [Full Text] [PDF] J. Cortes, E. Jabbour, H. Kantarjian, C. C. Yin, J. Shan, S. O'Brien, G. Garcia-Manero, F. Giles, M. Breeden, N. Reeves, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood, December 1, 2007; 110(12): 4005 - 4011. [Abstract] [Full Text] [PDF] H. Agis, W. R. Sperr, S. Herndlhofer, H. Semper, H. Pirc-Danoewinata, O. A. Haas, C. Mannhalter, H. Esterbauer, K. Geissler, C. Sillaber, et al. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571) Ann. Onc., November 1, 2007; 18(11): 1834 - 1841. [Abstract] [Full Text] [PDF] P. Kebriaei, M. A. Detry, S. Giralt, A. Carrasco-Yalan, A. Anagnostopoulos, D. Couriel, I. F. Khouri, P. Anderlini, C. Hosing, A. Alousi, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia Blood, November 1, 2007; 110(9): 3456 - 3462. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] D. White, V. Saunders, A. Grigg, C. Arthur, R. Filshie, M. F. Leahy, K. Lynch, L. B. To, and T. Hughes Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia J. Clin. Oncol., October 1, 2007; 25(28): 4445 - 4451. [Abstract] [Full Text] [PDF] T. O'Hare, C. A. Eide, and M. W. N. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood, October 1, 2007; 110(7): 2242 - 2249. [Abstract] [Full Text] [PDF] F. E. Nicolini, S. Hayette, S. Corm, E. Bachy, D. Bories, M. Tulliez, F. Guilhot, L. Legros, F. Maloisel, J.-J. Kiladjian, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation Haematologica, September 1, 2007; 92(9): 1238 - 1241. [Abstract] [Full Text] [PDF] M Devetten and J. Armitage Hematopoietic cell transplantation: progress and obstacles Ann. Onc., September 1, 2007; 18(9): 1450 - 1456. [Abstract] [Full Text] [PDF] C. A. Schiffer BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265. [Full Text] [PDF] A. S. M. Yong, K. Rezvani, B. N. Savani, R. Eniafe, S. Mielke, J. M. Goldman, and A. J. Barrett High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects Blood, July 15, 2007; 110(2): 770 - 775. [Abstract] [Full Text] [PDF] G. Volpe, A. Cignetti, C. Panuzzo, M. Kuka, K. Vitaggio, M. Brancaccio, G. Perrone, M. Rinaldi, G. Prato, M. Fava, et al. Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches Cancer Res., June 1, 2007; 67(11): 5300 - 5307. [Abstract] [Full Text] [PDF] F. Guilhot No more transplantation in CML? Blood, June 1, 2007; 109(11): 4592 - 4592. [Full Text] [PDF] R. Hehlmann, U. Berger, M. Pfirrmann, H. Heimpel, A. Hochhaus, J. Hasford, H.-J. Kolb, T. Lahaye, O. Maywald, A. Reiter, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia Blood, June 1, 2007; 109(11): 4686 - 4692. [Abstract] [Full Text] [PDF] M. W. Schellings, B. Lowenberg, Y. M. Pinto, and K. Strebhardt Another Look at Imatinib Mesylate N. Engl. J. Med., March 15, 2007; 356(11): 1183 - 1183. [Full Text] [PDF] A. Hochhaus, H. M. Kantarjian, M. Baccarani, J. H. Lipton, J. F. Apperley, B. J. Druker, T. Facon, S. L. Goldberg, F. Cervantes, D. Niederwieser, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood, March 15, 2007; 109(6): 2303 - 2309. [Abstract] [Full Text]